CSTL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Castle Biosciences Inc (CSTL) is not a strong buy at the moment for a beginner investor with a long-term strategy. The stock shows bearish technical indicators, insider selling activity, and weak financial performance. While analysts have raised price targets and maintain positive ratings, the lack of recent positive news, weak trading sentiment, and poor financial growth trends suggest holding off on investment until more favorable conditions arise.
The technical indicators for CSTL are bearish. The moving averages indicate a downward trend (SMA_200 > SMA_20 > SMA_5). The RSI is neutral at 27.158, and the MACD histogram is positive but contracting. The stock is trading below key pivot levels, with support at 24.313 and resistance at 26.453.
Analysts have raised price targets recently, with Baird, KeyBanc, and Guggenheim maintaining positive ratings and projecting significant upside potential.
Insiders are selling heavily, with a 1548.68% increase in selling activity over the last month. Financial performance in Q4 2025 was weak, with a significant drop in net income (-124.32% YoY) and EPS (-125.81% YoY). Additionally, there is no recent positive news or significant trading trends to support bullish sentiment.
In Q4 2025, revenue increased marginally by 0.81% YoY to $87,010,000. However, net income dropped significantly to -$2,332,000 (-124.32% YoY), and EPS declined to -0.08 (-125.81% YoY). Gross margin improved slightly to 76.33%, up 0.14% YoY.
Analysts maintain positive ratings with raised price targets: Baird ($44), KeyBanc ($50), and Guggenheim ($47). These updates reflect optimism based on Q4 results and management outlook.
